Avalyn Pharma Inc.
Avalyn Pharma Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF on December 15, 2026. There are 3 upcoming events on record.
Cash runway is approximately 35.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Trial Milestone | Phase 2 |
| June 15, 2027 | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Trial Milestone | Phase 2 |
| December 31, 2031 | An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Trial Milestone | Phase 2 |
Track AVLN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AVLN in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 16, 2026 | 8-K filed: Leadership change | Corporate | — |
| August 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 1, 2026 | 8-K filed: Material agreement | Corporate | — |
| June 17, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| June 3, 2026 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.